Search for content, post, videos

Results about Novo’s semaglutide

novo nordisk

Novo Nordisk’s semaglutide demonstrated superior improvements in glycaemic control vs sitagliptin (SUSTAIN 2) and exenatide ER (SUSTAIN 3) in two clinical trials in adults with type 2 diabetes.

Findings from two phase 3a clinical trials for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, were presented at the American Diabetes Association 76th Scientific Sessions. In the SUSTAIN 2 trial, 0.5 mg and 1.0 mg semaglutide administered once-weekly significantly improved glycaemic control compared to sitagliptin (100 mg), a dipeptidyl peptidase-4 (DPP-4) inhibitor, in adults with type 2 diabetes. In the SUSTAIN 3 trial, 1.0 mg semaglutide administered once-weekly significantly improved glycaemic control compared to 2.0 mg exenatide extended-release (ER), a GLP-1 receptor agonist, in adults with type 2 diabetes.

Leave a Reply

Your email address will not be published. Required fields are marked *

5 × 5 =